Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
86.6M
-
Number of holders
-
154
-
Total 13F shares, excl. options
-
71.3M
-
Shares change
-
+10.2M
-
Total reported value, excl. options
-
$1.82B
-
Value change
-
+$263M
-
Put/Call ratio
-
0.96
-
Number of buys
-
94
-
Number of sells
-
-46
-
Price
-
$25.45
Significant Holders of Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX) as of Q4 2022
169 filings reported holding SNDX - Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share as of Q4 2022.
Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX) has 154 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 71.3M shares
of 86.6M outstanding shares and own 82.42% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (7.98M shares), Avidity Partners Management LP (5.86M shares), BlackRock Inc. (4.35M shares), Frazier Life Sciences Management, L.P. (3.71M shares), STATE STREET CORP (3.65M shares), VANGUARD GROUP INC (3.36M shares), Avoro Capital Advisors LLC (2.65M shares), Kynam Capital Management, LP (2.56M shares), JENNISON ASSOCIATES LLC (2.3M shares), and ORBIMED ADVISORS LLC (2.01M shares).
This table shows the top 154 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.